RTI Surgical (RTIX) Reports In-Line Q4 EPS, Beats on Revenues; Offers FY18 Revenue Mid-Point Outlook Above Consensus

Note: EPS may not be comparable

RTI Surgical (NASDAQ: RTIX) reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $70.8 million versus the consensus estimate of $69.7 million.

• Net loss applicable to common shares was $8.6 million loss, or $0.14 per fully diluted common share in the fourth quarter of 2017, compared to a net loss applicable to common shares of $11.8 million, or $0.20 per fully diluted common share in the fourth quarter of 2016.
• As outlined in the reconciliation tables that follow, excluding the impact of the various non-recurring charges and the impact of the Tax Cuts and Jobs Act in the fourth quarter of 2017, adjusted net income applicable to common shares was $1.6 million, or $0.03 per fully diluted common share in the fourth quarter of 2017.

Fiscal 2018 Outlook

Based on its recent financial results and current business outlook, the Company is reiterating financial guidancefor 2018, originally issued on January 5, 2018:

• The Company expects full year revenues in the range of $280 million and $290 million.
• The Company expects full year EBITDA to be in the range of $32 million to $38 million.

The Company noted the following assumptions are included in its guidance:

• Relatively stable market conditions and regulatory environment;
• Positive revenue contribution from the acquisition of Zyga Technology – announced January 4th, 2018;
• Ongoing positive impact of efforts to reduce complexity and implement operational excellence; and
• Continued marketing of map3® cellular allogeneic bone graft and minimal negative revenue impact related to recent FDA warning letter.

GUIDANCE:

RTI Surgical sees FY2018 revenue of $280-290 million, versus the consensus of $281.07 million.

For earnings history and earnings-related data on RTI Surgical (RTIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat